AmgenvsSpero Therapeutics

AMGN and SPRO stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$462.32

Value $249B

-0.72%
AMGN's page

SPRO

Spero Therapeutics, Inc.

$0.95

Value $55M

-5.36%
SPRO's page

Amgen (AMGN) has a market value of $249B and Spero Therapeutics (SPRO) $55M. Over the last year, with dividends, AMGN moved +41.1% and SPRO -60.7%. Dividend yield: AMGN 2.15%, SPRO none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$249B

    SPRO$55M

    AMGN is 4,549 times SPRO

  • Revenue, 12 months

    AMGN$38.9B

    SPRO$42M

    AMGN is 936 times SPRO

  • Net income, 12 months

    AMGN$9.4B

    SPRO-$30M

  • Operating margin

    AMGN32.4%

    SPRO-67.3%

    99.7 points apart

  • ROIC

    AMGN16.2%

    SPRO-60.2%

    76.4 points apart

  • P/E

    AMGN26.5

    SPRO–

  • Dividend yield

    AMGN2.2%

    SPRO0.0%

    2.2 points apart

  • 5-year return

    AMGN+158.3%

    SPRO-94.2%

    252.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+158.3%

SPRO-94.2%

010020020222023202420252026
Returns by period
PeriodAMGNWith dividendsSPROWith dividends
1 year since November 14, 2025+41.1%Price +37.3%-60.7%Price -60.7%
3 years since November 16, 2023+86.6%+23.1% a yearPrice +71.9%-18.4%-6.6% a yearPrice -18.4%
5 years since November 15, 2021+158.3%+20.9% a yearPrice +122.9%-94.2%-43.5% a yearPrice -94.2%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenSPROSpero Therapeutics

Valuation

AMGNSPRO
Valuation
Price$462.32$0.95
Market value$249B$55M
Enterprise value (EV)$290B–
P/E26.5–
P/E, 5-year median23.0–
P/B17.470.2
EV/EBIT23.0–
Free cash flow yield3.8%–

Results and growth

AMGNSPRO
Results and growth
Revenue, 12 months$38.9B$42M
Net income, 12 months$9.4B-$30M
Free cash flow, 12 months$9.6B-$40M
Earnings per share, 12 months$17.25-$0.49
Revenue growth, year on year10.0%39.2%
Revenue growth a year, past+7.6%over 5 years+48.3%over 5 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNSPRO
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%-67.3%
Net margin24.1%-71.0%
ROIC16.2%-60.2%
ROE87.8%-80.5%

Balance sheet

AMGNSPRO
Balance sheet
Cash$13.2B$108M
Total debt$54.0B$1.6M
Net debt / EBITDA2.3–
Interest cover4.8×–

Dividends and buybacks

AMGNSPRO
Dividends and buybacks
Dividend yield2.2%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.2%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or SPRO

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Spero Therapeutics?

By market value, Amgen ($249B) is about 4,548.8 times Spero Therapeutics ($55M), at today's prices.

How did AMGN and SPRO stock do over the last 5 years?

Since November 15, 2021, AMGN's price moved +122.9% and SPRO's -94.2%. With dividends: AMGN +158.3% (+20.9% a year), SPRO -94.2% (-43.5% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or SPRO?

The dividend yield at today's price is 2.15% for Amgen and none for Spero Therapeutics. Over the last twelve months they paid $9.94 and – per share.

Which has the higher profit margins, Amgen or Spero Therapeutics?

Over the last twelve months, the net margin was 24.1% for Amgen and -71.0% for Spero Therapeutics, and the operating margin 32.4% and -67.3%. Revenue was $38.9B and $42M.

Which is the better investment, Amgen or Spero Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.